Mandate

Vinge is advising Nytida in connection with merger with the Solhaga Group

January 25, 2016

Vinge is advising Nytida, which is part of Ambea, in connection with the merger with Solhagagruppen (the “Solhaga Group”).

Nytida intends to merge with the Solhaga Group. Nytida and the Solhaga Group possess considerable experience and expertise within the fields of functional impairment and the Solhaga Group specializes in the fields of neuropsychiatric and psychiatric impairment and reduced development. Both Nytida and the Solhaga Group conduct operations throughout a large part of Sweden and provide accommodation, schooling, short-term accommodation and daytime activities. The Solhaga Group also conducts operations in Norway.

Closing of the transaction is subject to the customary approval of the relevant competition authority.

Vinge’s team consisted of, among others, partners Christina Kokko, Jonas Johansson, Louise Brorson Salomon and Marcus Glader together with associates Linda Sengul, Maria Dahlin, Albert Wållgren, Anna-Maria Terzi, Emil Fahlén Godö and Anne Wijkman.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026